For Research Use Only. Not for use in diagnostic procedures.

Lyophilized powder

Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.

Small volumes of Myh7 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

This is a synthetic peptide designed for use in combination with anti-Myh7 Antibody, made

Target Description: Myh7 play a role in muscle contraction.

Peptide

Immunohistochemistry (IHC), Western Blot (WB)

223kDa

myosin, heavy polypeptide 7, cardiac muscle, beta

myosin-7

Myosin-7

MyHC-slow; MyHC-beta??[Similar Products]

MYH7: Muscle contraction. Defects in MYH7 are the cause of familial hypertrophic cardiomyopathy type 1 (CMH1). Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in MYH7 are the cause of myopathy myosin storage (MYOMS). In this disorder, muscle biopsy shows type 1 fiber predominance and increased interstitial fat and connective tissue. Inclusion bodies consisting of the beta cardiac myosin heavy chain are present in the majority of type 1 fibers, but not in type 2 fibers. Defects in MYH7 are the cause of scapuloperoneal myopathy MYH7-related (SPMM); also known as scapuloperoneal syndrome myopathic type. SPMM is a progressive muscular atrophia beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. Defects in MYH7 are a cause of cardiomyopathy dilated type 1S (CMD1S). Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in MYH7 are the cause of myopathy distal type 1 (MPD1). MPD1 is a muscular disorder characterized by early-onset selective weakness of the great toe and ankle dorsiflexors, followed by weakness of the finger extensors. Mild proximal weakness occasionally develops years later after the onset of the disease.

Protein type: Motility/polarity/chemotaxis; Motor

Chromosomal Location of Human Ortholog: 14 C3|14 28.01 cM

Cellular Component: cytoplasm; muscle myosin complex; myofibril; myosin complex; sarcomere; stress fiber; Z disc

Molecular Function: actin binding; actin-dependent ATPase activity; ATP binding; ATPase activity; calmodulin binding; microfilament motor activity; motor activity; nucleotide binding; protein heterodimerization activity; protein homodimerization activity

Biological Process: ***** heart development; ATP metabolic process; cardiac muscle contraction; cardiac muscle hypertrophy in response to stress; muscle contraction; muscle filament sliding; regulation of heart rate; regulation of slow-twitch skeletal muscle fiber contraction; regulation of the force of heart contraction; regulation of the force of skeletal muscle contraction; skeletal muscle contraction; striated muscle contraction; transition between fast and slow fiber; ventricular cardiac muscle tissue morphogenesis

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.